skip to Main Content

Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease.


Maximus Peto’s Commentary

This group assesses nine potential Alzheimer’s biomarkers during the “preclinical phase” of Alzheimer’s disease to help determine whether, to what extent, and how early the disease process can be identified. CSF t-tau had the earliest noticeable changepoint (34 years prior to symptom onset, which suggests the disease process might be quite long).


Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease.
Front Aging Neurosci. 2019 Apr 2;11:74.
Younes L, Albert M, Moghekar A, Soldan A, Pettigrew C, Miller MI
DOI: 10.3389/fnagi.2019.00074
PubMed publication date (edat): 4/20/2019

Abstract

Objective: Several models have been proposed for the evolution of Alzheimer’s disease (AD) biomarkers. The aim of this study was to identify changepoints in a range of biomarkers during the preclinical phase of AD. Methods: We examined nine measures based on cerebrospinal fluid (CSF), magnetic resonance imaging (MRI) and cognitive testing, obtained from 306 cognitively normal individuals, a subset of whom subsequently progressed to the symptomatic phase of AD. A changepoint model was used to determine which of the measures had a significant change in slope in relation to clinical symptom onset. Results: All nine measures had significant changepoints, all of which preceded symptom onset, however, the timing of these changepoints varied considerably. A single measure, CSF t-tau, had an early changepoint (34 years prior to symptom onset). A group of measures, including the remaining CSF measures (CSF Abeta and phosphorylated tau) and all cognitive tests had changepoints 10-15 years prior to symptom onset. A second group is formed by medial temporal lobe shape composite measures, with a 6-year time difference between the right and left side (respectively nine and 3 years prior to symptom onset). Conclusion: These findings highlight the long period of time prior to symptom onset during which AD pathology is accumulating in the brain. There are several significant findings, including the early changes in cognition and the laterality of the MRI findings. Additional work is needed to clarify their significance.

PMID: 31001108
Free Full-Text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454004/

Maximus Peto

Max Peto is a longevity researcher and founder of Long Life Labs. A biochemist by training, he studies the biochemistry of aging and longevity and has worked with research organizations such as SENS Research Foundation, Methuselah Foundation, BioAge Labs, Life Extension Foundation, and Ichor Therapeutics. His work at Long Life Labs is focused on empowering people to understand and manage the most critical factors for better health and longer life.

Free report on high blood pressure

The American Heart Association estimates more than 100 million Americans have high blood pressure, also known as “hypertension”. Learn more about the cause of high blood pressure and how you can reverse it in our free report.

Coming soon. We’ll send you the report as soon as it’s published.

*We do not share your email address with anyone.

Free longevity biomarker report

Biomarker levels predict the risk of early death—and we can change them! Learn about some important longevity biomarkers in our free report.

Coming soon. We’ll send you the report as soon as it’s published.

*We do not share your email address with anyone.

Free diabetes report

An estimated 50% of American adults have either prediabetes or type 2 diabetes. Learn more about the cause of type 2 diabetes, prediabetes, insulin resistance, and how to reverse them in our free report.

Coming soon. We’ll send you the report as soon as it’s published.

*We do not share your email address with anyone.

Back To Top